Familial Hypercholesterolemia in the Czech Republic: More Than 17 Years of Systematic Screening Within the MedPed Project

Author:

VRABLÍK M.,VACLOVÁ M.,TICHÝ L.,SOŠKA V.,BLÁHA V.,FAJKUSOVÁ L.,ČEŠKA R.,ŠATNÝ M.,FREIBERGER T.1

Affiliation:

1. Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic

Abstract

Familial hypercholesterolemia (FH) is the most common autosomal dominant disorder. It is characterized by a decrease in LDL cholesterol catabolism and an early clinical manifestation of atherosclerotic vessel damage. The aim of the MedPed (Make early diagnosis to Prevent early deaths) project is an early diagnosis of FH patients in order to profit from early treatment and prevent cardiovascular events. Till November 30, 2016 The Czech National MedPed Database has registered 7,001 FH patients from 5,223 different families that is 17.4 % of expected patients in the Czech Republic considering 1:250 FH prevalence. The improvement in diagnostic accuracy, patient cooperation and above all familial cascade screening is enabled by FH mutation detection using the modern technology of next-generation sequencing. FH still remain undiagnosed even though the Czech Republic is one of the most successful countries with respect to FH detection. The opportunities of international collaboration and experience sharing within international programs (e.g. EAS FHSC, ScreenPro FH etc.) will improve the detection of FH patients in the future and enable even more accessible and accurate genetic diagnostics.

Publisher

Institute of Physiology of the Czech Academy of Sciences

Subject

General Medicine,Physiology

Reference28 articles.

1. BENN M, WATTS GF, TYBJAERG-HANSEN A, NORDESTGAARD B: Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 37: 1384-1394, 2016.

2. BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47, 1986.

3. CESKA R, FREIBERGER T, VACLOVA M, ALEKSICOVA T, VOTAVOVA L, VRABLIK M: ScreenPro FH: from the Czech MedPed to international collaboration. ScreenPro FH is a participating project of the EAS-FHCS. Physiol Res 66 (Suppl 1): S85-S90, 2017.

4. CTT (CHOLESTEROL TREATMENT TRIALISTS’) COLLABORATION: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681, 2010.

5. CUCHEL M, BRUCKERT E, GINSBERG HN, RAAL FJ, SANTOS RD, HEGELE RA, KUIVENHOVEN JA, NORDESTGAARD BG, DESCAMPS OS, STEINHAGEN-THIESSEN E, TYBJAERG-HANSEN A, WATTS GF, AVERNA M, BOILEAU C, BORÉN J, CATAPANO AL, DEFESCHE JC, HOVINGH GK, HUMPHRIES SE, KOVANEN PT, MASANA L, PAJUKANTA P, PARHOFER KG, RAY KK, STALENHOEF AF, STROES E, TASKINEN MR, WIEGMAN A, WIKLUND O, CHAPMAN MJ: European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia: Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35: 21, 2014.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3